Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab and Adalimumab Trough Levels and Efficacy in IBD
NCT05291039Completed
- Sponsor
- Rehab Werida
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of infliximab and adalimumab in inflammatory bowel disease (IBD) (2 arms), sponsored by Rehab Werida. Primary endpoints: Trough concentration of Adalimumab and Infliximab at 1 month and Myeloid cells 1 (TREM1) levels at 1 month. Started Jan 2022; status: completed.
02
Drugs
infliximabadalimumab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05291039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291039.